The biopharmaceutical company AELIX Therapeutics, member of CATALONIA.HEALTH, has announced that the US biotech company Gilead Sciences, Inc. has acquired the research assets related to its therapeutic HTI vaccine against HIV.
Thomas Hecht, Executive Chairman of AELIX, said: “We are excited that such a prominent company as Gilead, a leader in HIV treatment, prevention and cure research, has decided to acquire AELIX’s HTI therapeutic HIV vaccine investigational assets. The HTI vaccines have shown promising results in phase 1 and phase 2 clinical trials, and we are eager to see this immunogen move forward through this acquisition and potentially become an important aspect of the search for an HIV cure. We are thankful to our early-stage investors including Ysios Capital, which had the vision to support the development of potential HIV cure strategies.”
Christian Brander, CSO and co-founder of AELIX, added: “We are excited that our HTI T-cell immunogen is now in the hands of an innovative pharmaceutical company like Gilead Sciences, which has the tools and capabilities to further evaluate this asset as part of a potential approach to an HIV cure strategy.”
Related news:
Comments